Ihuman Stock Based Compensation vs Change To Liabilities Analysis
| IH Stock | USD 1.68 0.02 1.20% |
Ihuman financial indicator trend analysis is infinitely more than just investigating Ihuman Inc recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ihuman Inc is a good investment. Please check the relationship between Ihuman Stock Based Compensation and its Change To Liabilities accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ihuman Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Stock Based Compensation vs Change To Liabilities
Stock Based Compensation vs Change To Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ihuman Inc Stock Based Compensation account and Change To Liabilities. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Ihuman's Stock Based Compensation and Change To Liabilities is -0.63. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Change To Liabilities in the same time period over historical financial statements of Ihuman Inc, assuming nothing else is changed. The correlation between historical values of Ihuman's Stock Based Compensation and Change To Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Ihuman Inc are associated (or correlated) with its Change To Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change To Liabilities has no effect on the direction of Stock Based Compensation i.e., Ihuman's Stock Based Compensation and Change To Liabilities go up and down completely randomly.
Correlation Coefficient | -0.63 |
| Relationship Direction | Negative |
| Relationship Strength | Weak |
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Change To Liabilities
Most indicators from Ihuman's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ihuman Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ihuman Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. As of now, Ihuman's Tax Provision is increasing as compared to previous years. The Ihuman's current Enterprise Value Over EBITDA is estimated to increase to 26.87, while Selling General Administrative is projected to decrease to under 115.3 M.
| 2022 | 2023 | 2024 | 2025 (projected) | Gross Profit | 691.2M | 721.3M | 829.5M | 483.8M | Total Revenue | 985.5M | 1.0B | 1.2B | 702.3M |
Ihuman fundamental ratios Correlations
Click cells to compare fundamentals
Ihuman Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ihuman fundamental ratios Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 1.0B | 1.1B | 1.3B | 1.5B | 1.7B | 945.7M | |
| Other Current Liab | 90.1M | 104.7M | 118.8M | 438.0M | 503.7M | 528.8M | |
| Total Current Liabilities | 399.2M | 482.9M | 561.1M | 490.8M | 564.4M | 410.5M | |
| Total Stockholder Equity | 642.7M | 608.4M | 769.5M | 957.8M | 1.1B | 1.2B | |
| Property Plant And Equipment Net | 12.9M | 50.5M | 22.0M | 9.8M | 11.3M | 18.0M | |
| Current Deferred Revenue | 268.6M | 303.0M | 379.1M | 318.6M | 366.4M | 251.0M | |
| Net Debt | (855.1M) | (821.1M) | (1.0B) | (1.2B) | (1.1B) | (1.0B) | |
| Retained Earnings | (386.0M) | (423.0M) | (321.2M) | (140.5M) | (126.4M) | (132.7M) | |
| Accounts Payable | 21.6M | 30.5M | 24.2M | 22.1M | 25.5M | 22.3M | |
| Cash | 861.7M | 855.4M | 1.0B | 1.2B | 1.4B | 750.2M | |
| Non Current Assets Total | 25.5M | 85.6M | 79.6M | 68.1M | 78.3M | 48.6M | |
| Non Currrent Assets Other | 784K | 7.8M | 6.4M | 8.7M | 10.0M | 10.5M | |
| Other Assets | 2.7M | 784K | 7.8M | 6.4M | 7.4M | 4.0M | |
| Cash And Short Term Investments | 861.7M | 855.4M | 1.0B | 1.2B | 1.4B | 750.2M | |
| Net Receivables | 78.3M | 59.0M | 81.9M | 62.6M | 72.0M | 58.0M | |
| Common Stock Shares Outstanding | 226.3M | 266.6M | 270.2M | 273.8M | 314.8M | 206.7M | |
| Liabilities And Stockholders Equity | 1.0B | 1.1B | 1.3B | 1.5B | 1.7B | 945.7M | |
| Non Current Liabilities Total | 5.1M | 9.6M | 2.9M | 1.9M | 1.7M | 1.7M | |
| Capital Surpluse | 213.1M | 1.1B | 1.1B | 1.1B | 1.2B | 751.9M | |
| Inventory | 16.9M | 28.1M | 19.1M | 16.5M | 14.9M | 17.4M | |
| Other Current Assets | 64.6M | 72.9M | 102.8M | 89.5M | 102.9M | 60.9M | |
| Other Stockholder Equity | 1.1B | 1.1B | 1.1B | 1.1B | 1.2B | 844.0M | |
| Total Liab | 404.3M | 492.5M | 563.9M | 492.7M | 566.6M | 414.1M | |
| Net Invested Capital | 642.7M | 608.4M | 769.5M | 957.8M | 1.1B | 1.2B | |
| Total Current Assets | 1.0B | 1.0B | 1.3B | 1.4B | 1.6B | 897.1M | |
| Accumulated Other Comprehensive Income | (21.9M) | (34.7M) | 18.5M | 26.1M | 30.0M | 31.5M | |
| Cash And Equivalents | 104.9M | 861.7M | 855.4M | 1.0B | 1.2B | 633.2M | |
| Net Working Capital | 622.2M | 532.3M | 692.7M | 891.7M | 1.0B | 1.1B | |
| Short Term Debt | 1.5M | 24.7M | 6.1M | 1.9M | 1.7M | 1.6M | |
| Intangible Assets | 11.8M | 27.3M | 24.9M | 23.2M | 26.7M | 16.0M | |
| Property Plant Equipment | 2.5M | 12.9M | 50.5M | 22.0M | 25.3M | 19.5M | |
| Property Plant And Equipment Gross | 12.9M | 50.5M | 22.0M | 23.3M | 26.8M | 24.7M |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ihuman Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Hotels, Restaurants & Leisure space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ihuman. If investors know Ihuman will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ihuman listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.40) | Earnings Share 0.27 | Revenue Per Share | Quarterly Revenue Growth (0.11) | Return On Assets |
The market value of Ihuman Inc is measured differently than its book value, which is the value of Ihuman that is recorded on the company's balance sheet. Investors also form their own opinion of Ihuman's value that differs from its market value or its book value, called intrinsic value, which is Ihuman's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ihuman's market value can be influenced by many factors that don't directly affect Ihuman's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ihuman's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ihuman is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ihuman's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.